截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新紐科技有限公司（*僅供識別）（於開曼群島註冊成立有限公司） 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09600 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.000001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.000001 | USD | ...

Group 1 - The National Health Commission, the State Administration of Traditional Chinese Medicine, and the National Disease Control Bureau jointly issued a notice to strengthen the management of electronic medical record (EMR) information in medical institutions, focusing on internal management, standardizing EMR usage, and enhancing regulatory oversight [1] - New New Technology Co., Ltd. is a technology-driven IT solution provider that leverages AI and big data to support the digital transformation of the healthcare industry, offering innovative IT solutions to optimize medical safety and internal management for healthcare institutions [1][2] - The company's medical and medical record quality management products comply with national standards and effectively assist healthcare clients in achieving accurate verification of medical record completeness, timeliness, logical consistency, and compliance with medical norms [2] Group 2 - The products support flexible hierarchical management and configuration, allowing clients to set specific quality control standards and management permissions based on various dimensions such as department, management level, and record type [3] - The company aims to enhance its competitive advantage by continuously improving the integration of AI and big data technologies in the healthcare information sector, contributing to the overall improvement of healthcare service quality management in China [3]

Group 1 - Yuxin Technology has submitted an application for overseas listing on the Hong Kong Stock Exchange to support its overseas business development and enhance its international brand image and competitiveness [1] - Changliang Technology has provided trading system solutions to multiple institutions that have obtained virtual banking licenses in Hong Kong, indicating a positive outlook for its overseas business starting from 2025 [1] - The trend of Chinese fintech companies expanding internationally is driven by the acceleration of global digitalization and increasing domestic market competition [2] Group 2 - Hong Kong has become a strategic hub for many mainland fintech companies looking to enter global markets, with over 1,100 fintech firms currently operating in the region [3] - The integration of the Guangdong-Hong Kong-Macao Greater Bay Area is expected to enhance Hong Kong's role as a facilitator for mainland tech companies to connect internationally [3] - Hong Kong is anticipated to evolve from a "super connector" to a "super value creator," aiding in the high-quality development of national and industrial sectors [3]

Group 1 - New New Technology Co., Ltd. (stock code: 9600.HK) has gained industry attention for its deep expertise and innovative exploration in the field of medical information technology [1] - At the 6th Public Hospital High-Quality Innovation Development Exchange Conference, New New's subsidiary, Beijing New New Technology Co., Ltd., showcased its AI-based medical record quality control system, which has improved medical record writing standardization and diagnostic accuracy [1] - The system has been implemented in several top-tier hospitals in China, enhancing medical record review efficiency by over 40% and achieving a diagnostic suggestion accuracy rate exceeding 92% [1] Group 2 - The National Health Commission has drafted the "Smart Medical Grading Evaluation Method and Standards (2025 Edition)," which includes new evaluation requirements for artificial intelligence and domestic substitution [2] - New New Technology has been a pioneer in leveraging AI and big data analytics to support the digital transformation of the healthcare industry, providing various innovative IT solutions and products [2] - The company is actively developing new products and technologies in response to ongoing healthcare policy reforms, enhancing its medical record quality monitoring and warning platform with advanced capabilities [2] Group 3 - Beijing New New Technology Co., Ltd. has reached a project consulting cooperation with a well-known large state-owned enterprise to upgrade health management services through intelligent technology [3] - The collaboration will focus on the localized deployment of the DeepSeek large language model and private model training methods in core medical scenarios such as health education and consultation [3] - This partnership represents a successful practice in assisting medium and large state-owned enterprises in their digital transformation and aims to promote the accessibility of quality medical resources [3]

Group 1 - The core initiative of the company is the "Green Climbing Responsibility Together" event, which is part of its 2025 ESG series actions aimed at promoting a healthy lifestyle and sustainable development principles [1][3] - The event took place at Xiangshan Park in Beijing, with enthusiastic participation from employees of the company and its local branches, highlighting the company's commitment to environmental, social, and governance (ESG) practices [1][3] - Participants were encouraged to use public transport, cycling, or carpooling to reduce carbon emissions, and they brought reusable water bottles, demonstrating a commitment to sustainability during the event [1][3] Group 2 - The successful completion of the climbing challenge at Xianglu Peak symbolized the company's dedication to measuring environmental responsibility through action, encapsulated in the phrase "measuring green mountains with footsteps, interpreting responsibility through action" [3] - Following this event, the company plans to launch additional ESG activities themed around "Warmth of Clothing Continues Love," promoting green low-carbon living and encouraging employees to care for their well-being and give back to society [3] - The company aims to integrate sustainable development principles into its daily operations and deepen its responsibility practices in the ESG domain, thereby creating more value for society [3]

Group 1 - The National Health Commission is revising the "Smart Medical Level Evaluation Method and Standards (2025 Edition)" to promote the construction of smart hospitals, focusing on the integration of smart medical, smart services, and smart management [1] - The new standards will optimize evaluation levels, indicators, roles, and projects, while adding requirements for artificial intelligence and domestic product substitution [1] - The initiative encourages medical institutions to adopt new technologies and self-innovated products to drive innovation and development in medical services [1] Group 2 - New New Technology Co., Ltd. is a leading IT solution provider in China's healthcare sector, leveraging AI and big data to support the digital transformation of the medical industry [2] - The company offers various innovative IT solutions, including medical quality control and safety warning platforms, to enhance medical quality and internal management efficiency [2] - With the implementation of new medical policies, New New Technology continues to develop and innovate new products and technologies for better integration in medical record quality control and management [2] Group 3 - The company's medical record quality control products have integrated advanced technologies such as multi-dimensional data analysis, natural language processing (NLP), and large models [3] - The updated products provide enhanced capabilities in quality control and knowledge base retrieval, transitioning towards more precise applications [3] - New New Technology aims to continuously improve its product service levels and capabilities to support the digital transformation of the healthcare industry, contributing to the effective release of high-quality medical service system values [3]

Financial Performance - Newlink Technology Inc. reported a revenue increase of 15% year-over-year, reaching $120 million for the fiscal year 2024[4]. - In 2024, the company achieved a revenue growth of 13.6% compared to 2023, reaching RMB 278.8 million[17]. - The company projects a revenue growth of 20% for the next fiscal year, targeting $144 million[4]. - Gross profit for 2024 increased by 4.9% year-on-year, amounting to RMB 38.9 million[17]. - The gross margin improved to 45%, up from 40% in the previous year[4]. - The company recorded a net loss of RMB 93.0 million for 2024, compared to a loss of RMB 69.7 million in 2023[15]. - The pre-tax loss for 2024 was RMB 96.1 million, compared to a pre-tax loss of RMB 71.0 million in 2023[64]. - Annual loss for 2024 was RMB 93.0 million, a 33.4% increase from RMB 69.7 million in 2023, mainly due to losses from equity investments and increased operating expenses[66]. User Growth and Market Expansion - The user base expanded by 25%, with active users now totaling 1.5 million[4]. - The company plans to enter two new international markets by Q3 2025, aiming to increase global presence[4]. - The establishment of a new subsidiary in Shanxi aims to enhance the company's market strategy in North China[12]. - The company has established a stable customer base, including 10 Fortune 500 clients and 12 China 500 clients, contributing to its revenue growth[41]. Research and Development - Newlink is investing $10 million in R&D for new product development, focusing on AI and automation technologies[4]. - R&D expenditure for 2024 was RMB 71.5 million, a 69.0% increase from RMB 42.3 million in 2023, driven by increased amortization of deferred development costs and direct R&D expenses[60]. - The company continues to focus on R&D in AI and big data analytics, enhancing its IT solutions to meet customer needs[42]. Corporate Governance - The board consists of six directors, including three executive directors and three independent non-executive directors[22]. - The board's composition ensures a balance of executive and independent oversight, enhancing corporate governance[26]. - The board is committed to maintaining high standards of corporate governance to enhance shareholder value and transparency[97]. - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, to oversee specific aspects of the company's affairs[120]. Shareholder Engagement - The company has a dividend policy that allows for the declaration of dividends at the shareholders' meeting, provided it does not impair the company's ability to meet its debts[149]. - The company emphasizes effective communication with shareholders to enhance investor relations and understanding of business performance and strategy[155]. - The company has established procedures for shareholders to request special meetings, requiring at least 10% of voting shares[151]. Awards and Recognition - The company received multiple awards in 2024, including the "Industry Influence Award" and "Outstanding Medical Technology Innovation Award"[14]. - Newlink Technology was selected as one of the "Top 100 Financial Technology Companies in China" at the 2024 Zhongguancun Forum, highlighting its competitive position in the fintech sector[173]. - The company received the "2023 Outstanding Service Partner Award" from a major joint-stock bank client, indicating strong client relationships and service quality[169]. Environmental, Social, and Governance (ESG) - Newlink Technology emphasizes environmental protection as a key development strategy while pursuing its business goals, reflecting its commitment to ESG principles[168]. - The board is committed to monitoring ESG risks and adjusting business strategies accordingly, ensuring effective management of ESG issues[181]. - The company has set quantifiable environmental goals related to greenhouse gas emissions, resource consumption, and waste management[182]. - The ESG governance structure includes an ESG working committee and cross-departmental teams to implement and track ESG policies[184].

Core Insights - New New Technology (09600.HK) reported a revenue of RMB 278.8 million for 2024, representing a year-on-year growth of 13.6% compared to 2023 [1] - The company's gross profit increased by 4.9% year-on-year to RMB 38.9 million in 2024 [1] - The software development services segment generated RMB 243.2 million in revenue, accounting for 87.2% of total revenue, with a significant year-on-year growth of 35.5% [1] Financial Performance - Operating cash flow net income reached RMB 24.0 million, a substantial increase of 116.2% from RMB 11.1 million in 2023 [1] - Despite not achieving profitability in 2024, the growth in main business revenue and gross profit, along with the increase in operating cash flow, is expected to lay a solid foundation for rapid business development in 2025 [2] Strategic Developments - The company has established new subsidiaries in multiple locations including Hong Kong, Shenzhen, and Shanxi to enhance market presence and promote diversified collaborative development [1] - New New Technology focuses on "technological research and innovation" and "business model innovation," leveraging advanced technologies such as artificial intelligence and big data analytics for new product development and service integration [2] - The company has shown resilience despite challenges from a slowing domestic economy and complex external environments, maintaining steady business operations and gradually forming a stable operational style [2]

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 278,822 thousand, an increase of 13.6% from RMB 245,495 thousand in 2023[4] - Gross profit for 2024 was RMB 38,869 thousand, up from RMB 37,091 thousand in 2023, reflecting a gross margin of 13.9%[4] - The company reported a loss before tax of RMB 96,068 thousand for 2024, compared to a loss of RMB 70,971 thousand in 2023, indicating a deterioration in financial performance[4] - The net loss attributable to owners of the company for 2024 was RMB 92,463 thousand, compared to RMB 69,159 thousand in 2023, representing a 33.8% increase in losses[8] - Basic and diluted loss per share for 2024 was RMB (10.44), compared to RMB (8.79) in 2023, indicating a worsening loss per share[7] - The company recorded a pre-tax loss of RMB 96.1 million in 2024, compared to a pre-tax loss of RMB 71.0 million in 2023[83] - Annual loss expanded by 33.4% to RMB 93.0 million, influenced by losses from equity investments and increased operating expenses[85] Revenue Breakdown - Software development services generated RMB 243,195 thousand in 2024, up from RMB 179,490 thousand in 2023, reflecting a growth of 35.5%[31] - Technical and maintenance services revenue decreased to RMB 26,982 thousand in 2024 from RMB 37,644 thousand in 2023, a decline of 28.5%[31] - Standard software sales dropped significantly to RMB 8,645 thousand in 2024 from RMB 28,361 thousand in 2023, a decrease of 69.5%[31] - In 2024, the software development services generated revenue of RMB 243.2 million, accounting for 87.2% of total revenue, representing a year-on-year growth of 35.5%[68] - Innovative solutions contributed RMB 80.2 million to software development services revenue, making up 33.0% of that segment[68] - Revenue from technical and maintenance services decreased by 28.2% to RMB 27.0 million, representing only 9.7% of total revenue in 2024[69] - Standard software sales generated RMB 8.6 million, accounting for 3.1% of total revenue, with innovative solutions contributing 94.2% of this segment[70] Assets and Liabilities - Total assets decreased to RMB 882,822 thousand in 2024 from RMB 947,685 thousand in 2023, a decline of 6.9%[6] - Total liabilities decreased to RMB 143,384 thousand in 2024 from RMB 158,781 thousand in 2023, a reduction of 9.7%[6] - The company’s equity attributable to owners decreased to RMB 739,268 thousand in 2024 from RMB 786,971 thousand in 2023, a decline of 6.0%[10] - Accounts receivable decreased to RMB 203,965,000 from RMB 261,866,000, a reduction of 22%[43] - The company reported a total of RMB 60.856 million in accounts payable as of the reporting period end, down from RMB 71.741 million in 2023[48] Research and Development - Research and development expenses rose significantly to RMB 71,524 thousand in 2024 from RMB 42,315 thousand in 2023, an increase of 68.9%[7] - Research and development expenses surged by 69.0% to RMB 71.5 million, driven by increased direct spending and deferred development cost amortization[79] Cash Flow and Liquidity - The company’s cash and cash equivalents increased to RMB 348,240 thousand in 2024 from RMB 330,458 thousand in 2023, showing a slight improvement in liquidity[10] - The net cash generated from operating activities significantly increased by 116.2%, amounting to RMB 24.0 million in 2024, up from RMB 11.1 million in 2023[53] - Operating cash inflow reached RMB 24.0 million, a significant increase of 116.2% compared to RMB 11.1 million in 2023[86] Market and Strategic Initiatives - The company plans to enhance its market penetration in the Greater Bay Area and expand its solutions and products across broader regional markets[52] - The group plans to implement a dual-path expansion strategy focusing on "core area penetration and emerging market cultivation" to enhance its competitive edge by 2025[64] - The group aims to strengthen its cash flow management and optimize asset allocation to enhance operational resilience and risk management capabilities[65] Corporate Governance and Compliance - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2024, confirming compliance with applicable accounting standards[125] - The company has adopted all applicable principles and code provisions of the Corporate Governance Code as a benchmark for its governance practices[123] Employee and Shareholder Matters - The employee cost for 2024, including director remuneration, was approximately RMB 152.6 million, with a total of 622 employees as of December 31, 2024[114] - The board has resolved not to recommend any final dividend for the year ending December 31, 2024[120] - The company repurchased a total of 5,952,800 shares at a total cost of approximately HKD 2.47 million, reflecting confidence in its business outlook[118]

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 122,905,000, an increase of 4.9% compared to RMB 117,953,000 for the same period in 2023[11]. - Gross profit for the same period was RMB 24,725,000, a decrease of 1.4% from RMB 25,064,000 in 2023[11]. - The company reported a pre-tax loss of RMB (55,403,000), compared to a loss of RMB (26,525,000) in the previous year, indicating a significant increase in losses[11]. - The net loss for the period was RMB (55,418,000), compared to a loss of RMB (27,007,000) in 2023, highlighting worsening financial performance[11]. - Basic and diluted loss per share for the period was RMB (6.67), compared to RMB (3.40) for the same period in 2023[68]. - The company reported a loss attributable to shareholders of RMB 552 million, an increase of RMB 284 million year-on-year[13]. - The company reported a net amount of approximately HKD 790.4 million from its global offering, with an oversubscription amount of HKD 140.3 million[54]. - The group reported a pre-tax loss of RMB 55,226,000 for the six months ended June 30, 2024, compared to a loss of RMB 26,758,000 for the same period in 2023, indicating an increase in losses[86]. Assets and Liabilities - Total assets as of June 30, 2024, were RMB 945,290,000, slightly down from RMB 947,685,000 at the end of 2023[11]. - Total liabilities increased to RMB 175,035,000 from RMB 158,781,000 at the end of 2023, reflecting a rise in financial obligations[11]. - The total equity decreased to RMB 770,255,000 from RMB 788,904,000, indicating a decline in shareholder value[11]. - Cash and cash equivalents amounted to RMB 303.6 million as of June 30, 2024[21]. - The company's equity return rate decreased from -3.2% for the six months ended June 30, 2023, to -7.2% for the six months ended June 30, 2024, primarily due to losses incurred[42]. - The asset-liability ratio increased from 1.0% as of December 31, 2023, to 2.6% as of June 30, 2024, mainly due to an increase in bank borrowings[42]. - As of June 30, 2024, the company's accounts receivable amounted to RMB 262.6 million, with a recorded impairment loss of RMB 54.4 million[38]. - Accounts receivable decreased to RMB 208,193,000 from RMB 218,549,000, a decline of approximately 4.7%[69]. - The company reported a total equity of RMB 770,255,000 as of June 30, 2024, down from RMB 788,904,000, a decrease of about 2.3%[70]. Revenue Breakdown - In the first half of 2024, the company achieved a revenue of RMB 1.229 billion, representing a slight increase of 4.2% year-on-year[13]. - The software development services contributed 85.3% of total revenue, with a significant year-on-year increase of 25.7% to RMB 1.048 billion[13]. - Revenue from innovative solutions utilizing AI and big data analytics reached RMB 601 million, accounting for 57.3% of the software development services revenue[13]. - Revenue from software development services rose by 25.7% to RMB 104.8 million, accounting for 85.3% of total revenue[16]. - Revenue from technical and maintenance services generated RMB 13,839,000, and standard software sales contributed RMB 4,297,000 for the six months ended June 30, 2024[79]. Research and Development - The company has faced increased R&D expenses due to a rise in deferred development costs and the number of research projects[13]. - Research and development expenses surged by 106.6% to RMB 37.6 million, driven by increased project numbers and deferred development cost amortization[25]. - Research and development expenses for the current period amounted to RMB 37,648,000, up from RMB 18,202,000 in the previous year, reflecting a significant increase in investment in innovation[86]. Corporate Governance - The board believes that maintaining high corporate governance standards is crucial for protecting shareholder interests and enhancing corporate value[48]. - The company has complied with the corporate governance code, with the exception of the separation of roles between the chairman and CEO, which is held by Mr. Zhai[49]. - All directors confirmed compliance with the securities trading standard code during the six months ended June 30, 2024[50]. Future Outlook - Future outlook includes potential market expansion and new product development strategies, although specific figures were not disclosed in the report[11]. - The company plans to enhance its focus on technology innovation and expand its market presence in the second half of 2024[15]. - The company aims to improve its organizational processes and talent management to support future growth[15]. Employee and Management Information - As of June 30, 2024, the group had 615 employees, a decrease of 83 employees year-on-year[43]. - Employee costs, including director remuneration, amounted to approximately RMB 65.8 million for the six months ended June 30, 2024[43]. - The management compensation for the first half of 2024 was RMB 1,656,000, an increase of 25% compared to RMB 1,325,000 in the same period of 2023[106]. Cash Flow and Financing - The net cash used in operating activities for the six months ended June 30, 2024, was RMB 34,291,000, compared to RMB 30,896,000 for the same period in 2023, representing an increase of approximately 7.5%[72]. - The financing activities net cash inflow for the six months ended June 30, 2024, was RMB 47,618,000, compared to a net cash outflow of RMB 21,196,000 in 2023, indicating a positive shift in financing[72]. - The company issued 157,302,880 new ordinary shares at a subscription price of HKD 0.28 per share, raising approximately RMB 39,661 thousand for general working capital[101]. Awards and Recognition - The company received multiple industry awards, including the "2024 Outstanding Medical Technology Innovation Award" and "2024 Digital Innovation Enterprise Award" in 2024[14].